Table 2.
Laboratory, coagulation and fibrinolysis parameters stratified by median GDF-15 level
| Variable | Whole group, n = 103 | Low GDF-15 (445.3–1628.0 pg/mL, n = 51) | High GDF-15 (1661.0–5163.0 pg/mL, n = 52) | P value |
|---|---|---|---|---|
| Laboratory parameters | ||||
| GFR (mL/min) | 73.0 (56.0–85.0) | 74.0 (56.0–85.0) | 73.0 (53.0–85.3) | 0.70 |
| CRP (mg/L)* | 1.7 (1.0–3.4) | 1.7 (1.0–3.2) | 1.6 (1.0–3.6) | 0.73 |
| GDF-15 (pg/mL) | 1661.0 (1094.0–2417.0) | 1094.0 (834.2–1413.0) | 2407.0 (1830.0–3175.8) | < 0.0001 |
|
NT-proBNP (pg/mL) |
721.0 (401.0–1396.0) | 634.0 (440.0–1009.0) | 1086.5 (398.8–1694.5) | 0.09 |
| cTnI-hs (ng/l) | 6.1 (5.0–7.5) | 5.7 (4.6–7.1) | 6.4 (5.5–8.3) | 0.0099 |
| Coagulation and fibrinolysis parameters | ||||
| APTT (s) | 27.8 ± 3.8 | 27.5 ± 4.3 | 28.0 ± 3.2 | 0.48 |
| INR | 1.0 (1.0–1.1) | 1.1 (1.0–1.1) | 1.0 (1.0–1.1) | 0.45 |
| Fibrinogen (g/l)* | 3.4 (2.7–4.1) | 3.7 (3.2–4.0) | 3.2 (2.4–4.1) | 0.047 |
| vWF:Ag (%) | 187.0 (151.0–234.0) | 183.0 (135.0–220.0) | 190.0 (155.8–243.8) | 0.22 |
| TAFI:Ag (%) | 102.0 (94.0–113.0) | 105.0 (95.0–113.0) | 100.0 (91.0–114.5) | 0.51 |
| Plasminogen (%) | 105.6 ± 14.3 | 103.7 ± 12.5 | 107.4 ± 15.7 | 0.19 |
| Antiplasmin (%) | 106.0 (96.0–115.0) | 107.0 (96.0–117.0) | 103.5 (95.0–114.0) | 0.70 |
| tPA:Ag (ng/mL) | 7.2 (5.7–9.8) | 7.0 (5.9–8.0) | 7.6 (5.5–10.3) | 0.49 |
| PAI-1:Ag (ng/mL) | 15.6 ± 4.0 | 15.4 ± 3.8 | 15.8 ± 4.3 | 0.67 |
| ETP (nM × min) | 1488.0 (1403.0–1578.0) | 1453.0 (1374.0–1521.0) | 1502.5 (1447.8–1610.3) | 0.01 |
| Ks (× 10−9 cm2) | 6.6 ± 0.9 | 6.6 ± 0.9 | 6.6 ± 0.9 | 0.69 |
| CLT (min) | 98.0 (81.0–109.0) | 86.0 (76.0–100.0) | 102.5 (94.3–117.5) | < 0.0001 |
Data are presented as mean ± standard deviation or median (interquartile range)
APTT activated partial thromboplastin time, CLT clot lysis time, CRP C-reactive protein, cTnI-hs high-sensitivity cardiac troponin I, ETP endogenous thrombin potential, GFR glomerular filtration rate, INR international normalized ratio, Ks clot permeability, NT-proBNP N-terminal pro-B-type natriuretic peptide, PAI-1 plasminogen activator inhibitor-1, TAFI thrombin-activatable fibrinolysis inhibitor, tPA tissue-type plasminogen activator, vWF von Willebrand factor For other abbreviations see Table 1
*The data for fibrinogen and cTnI-hs were available for 101 patients, while the data for CRP were available for 100 patients